RXRX
Recursion Pharmaceuticals, Inc.4.2000
+0.0000+0%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
2.19BP/E (TTM)
-Basic EPS (TTM)
-1.84Dividend Yield
0%Recent Filings
8-K
8-K
8-K
Recursion Q2 earnings milestone
Recursion Pharmaceuticals reported Q2 2025 results, highlighting a $7 million Sanofi milestone for an immunology program, the fourth in 18 months, while advancing internal pipeline with REC-1245 enrolling in DAHLIA for replication stress tumors and REC-617 initiating ovarian cancer combinations in ELUCIDATE. Revenue climbed to $19.2 million from collaborations, yet net loss widened to $171.9 million amid $128.6 million R&D spend, driven by Exscientia integration and Tempus data deal. Cash stands at $533.8 million, funding into Q4 2027. Pipeline momentum builds.
10-Q
Q2 FY2025 results
Recursion Pharmaceuticals posted Q2 revenue of $19.2M, up 33% y/y from $14.4M, fueled by progress in Sanofi, Roche, and Merck collaborations, while YTD revenue climbed 20% to $34.0M. Yet operating losses widened to $176.2M from $100.5M y/y, driven by $128.6M in R&D expenses including $22.7M for Tempus data buys and Exscientia integration costs; net loss hit $171.9M or $(0.41) per share on 417M diluted shares, matching prior-year EPS of $(0.40) despite share growth. Cash dipped to $525.1M from $594.4M year-end, with negative FCF of $222.4M (derived) after $208.4M operating outflow and $14.0M capex; total debt stands at $22.9M in leases. The November 2024 Exscientia buy added $103.7M goodwill and $311M intangibles (6-year life for platform), boosting UK revenue to 38% of total. Ongoing securities suits from Exscientia's past cloud the horizon.
8-K
Recursion acquires full REV102 rights
Recursion Pharmaceuticals acquired Rallybio's 50% stake in their ENPP1 JV on July 8, 2025, gaining full ownership of the REV102 program—a preclinical oral inhibitor targeting hypophosphatasia. The deal included 1,457,952 shares worth $7.5 million upfront, plus $12.5 million in contingent shares and $5 million milestone cash upon Phase 1 start, with low single-digit royalties. This bolsters Recursion's pipeline for a rare disease with limited treatments. Phase 1 trials are slated for late 2026.
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
HEPA
Hepion Pharmaceuticals, Inc.
0.07-0.01
NRIX
Nurix Therapeutics, Inc.
18.84-0.17
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
PHIO
Phio Pharmaceuticals Corp.
1.08-0.01
RAPT
RAPT Therapeutics, Inc.
34.03+0.81
RNTX
Rein Therapeutics, Inc.
1.35-0.13
RPTX
Repare Therapeutics Inc.
2.23+0.03
SLXN
Silexion Therapeutics Corp
2.61+0.05
XFOR
X4 Pharmaceuticals, Inc.
3.71-0.05